30/07/2024 - Institutional news
Dr. Arnau Busquets, coordinator of the Research Group on Cellular Mechanisms in Physiological and Pathological Behavior at the Hospital del Mar Research Institute, has been selected in the Leonardo grants to support science and culture of excellence, awarded by the BBVA Foundation. In total, 58 projects have been selected, 18 of which in Catalonia. The project led by Dr. Busquets, 'Identifying brain circuits involved in emotional recognition', has been one of the six winners in this edition in the category of Biology and Biomedicine. The aim of the project is to identify the specific brain circuits involved in empathy processes that may be involved in complex social deficits observed in some neurodevelopmental disorders or neurodegenerative diseases. To identify them, a specific mouse model and pharmacogenetic techniques will be used.
Més informació "The BBVA Foundation awards one of its Leonardo grants to Dr. Arnau Busquets."
24/05/2024 - General information
Dr. Marta Torrens, Emeritus Director of Addictions of the Mental Health Institute of the Hospital del Mar and researcher of her research institute, has been selected by the executive committee of the European Union Drugs Agency (EUDA), to be part of its scientific committee. The decision was made on July 4 and Dr. Torrens will be one of the agency's advisors for the next four years. The European Union Agency for Drugs and Drug Addiction is the successor of the former European Monitoring Centre for Drugs and Drug Addiction, with enhanced capabilities and responsibilities.
18/07/2024 - General information
The Hospital del Mar Research Institute will be Olympic again. Three of the professionals of the Institute's Anti-Doping Laboratory of Catalonia will work in the Olympic Laboratory during the Olympic and Paralympic Games in Paris. They are Sergi Coll and Lídia Requena, who will travel to Paris to work at the Laboratory from July 26 to August 11 during the Olympic Games, and Indira Anselmo, who will work from August 28 to September 8, during the Paralympic Games. Sergi Coll is a specialist in the detection of anabolic steroids, and Lídia Requena and Indira Anselmo are specialists in the detection of hormones (erythropoietin, growth hormone...) and blood transfusions.
29/05/2024 - Press release
An international study led by the Hospital del Mar Medical Research Institute has demonstrated, for the first time, the role of two proteins in the activation and deactivation of the system through which drugs act against schizophrenia symptoms. These two proteins are potential targets for developing new drugs aimed at specific symptoms of the disease, avoiding the side effects of current treatments. The study analyzed how certain molecules act on a serotonin cell receptor, which could allow for differentiated effects on schizophrenia symptoms without affecting other brain processes.
Més informació "New Avenues to Developing Personalized Treatments for Schizophrenia"
30/04/2024 - Institutional news
Researchers from the Neuroscience Research Program, in conjunction with the University of Minnesota in the United States, will conduct the first meta-analysis with individual data on this issue. They will analyze data from more than 30,000 people in the United States and four European countries. The aim is to obtain recommendations so that governments can establish dietary guidelines to prevent the onset of diseases such as Alzheimer's disease. Is there any type of diet that really works to prevent cognitive decline? Despite all the publications on this question, the scientific evidence is not conclusive. For this reason, the Institute for the Advancement of Foord and Nutrition Sciences (IAFNS), in the United States, a body that acts as an advisor to the US government, has commissioned the Hospital del Mar Research Institute and the Epidemiology and Community Health Division of the University of Minnesota School of Public Health to conduct the first meta-analysis with individual data on the question.
21/02/2024 - Press release
This is an international collaborative work coordinated by the Hospital del Mar Research Institut and the Hospital Clínic-IDIBAPS, published in the Journal of Neurology. This new tool may make it possible to adapt the monitoring and treatment of patients to their future evolution, opting for the most effective, but with more possible side effects in those with worse prognosis. The exact factors behind the progression of disability in multiple sclerosis, a disease with great heterogeneity, are unknown, which is why it is so important to have tools of this type.
19/02/2024 - General information
The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with SXF, the most common form of hereditary intellectual disability without specific treatment. The public-private consortium formed by the biotechnology company CONNECTA Therapeutics, the Hospital del Mar Research Institute, the Center for Genomic Regulation (CRG), and the Parc Taulí Research and Innovation Institute (I3PT) will receive 2,7 million euros in funding from the Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program, to initiate Phase IIa clinical trials of the drug CTH120 for the treatment of Fragile X syndrome (Fragile X syndrome).
Més informació "Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome"
09/02/2024 - Press release
An international study has used a computational biology tool that, by analysing a multitude of biological data from multiple sclerosis patients ranging from genetic information to the whole organism, reveals the relationship between elements of different biological scales and improves our knowledge and the diagnosis of the disease. International research led by the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University, in collaboration with Hospital del Mar, Hospital Clínic, Charité - Medical University of Berlin, and the universities of Oslo and Genoa, has developed a computational biology tool, based on multi-level network analysis, to achieve an integrated vision of multiple sclerosis. This tool could be used to study other complex diseases such as types of dementia.
02/02/2024 - Institutional news
The laboratory director, Dr. Rosa Ventura Alemany, has been invited to join different expert committees of the agency starting this year. Dr. Ventura will be a member of the expert committee of anti-doping laboratories, which has the function of managing and monitoring the accreditation of laboratories and updating the regulations of the World Anti-Doping Agency (WADA). In addition, she will also be a member of the working group on the use of dried blood spots (DBS) in doping controls and of the MRPL (minimum required performance levels) working group, which defines the detection limits that laboratories have to achieve for the different substances prohibited in sport in order to perform effective doping controls.
10/01/2024 - Press release
Functional alterations in the brains of individuals with this condition coincide with the distribution of these neurons in the same brain. These neurons are responsible for filtering external information reaching the brain. Their functioning is altered in individuals with schizophrenia, which explains the majority of their symptoms. This discovery is the first time that this alteration can be identified as a possible origin of schizophrenic symptoms, and it opens the door to seeking new targeted treatments with fewer patient side effects.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
